Table 1 Clinical information of train and validation datasets in TCGA_UVM cohort and HX cohort. IQR means interquartile range

n

56

24

67

futime (median [IQR])

759.50 [466.25, 1159.75]

816.00 [352.00, 1290.25]

1590.00 [555.00, 2280.00]

1.93E-04

Kruskal–Wallis Test

fustat (median [IQR])

0.00 [0.00, 1.00]

0.00 [0.00, 1.00]

0.00 [0.00, 0.00]

9.57E-01

Kruskal–Wallis Test

age (median [IQR])

60.00 [49.75, 74.00]

64.00 [54.00, 76.00]

52.00 [41.00, 59.00]

2.89E-05

Kruskal–Wallis Test

gender (%)

female

24 (42.9)

11 (45.8)

31 (46.3)

9.26E-01

Chisq Test

male

32 (57.1)

13 (54.2)

36 (53.7)

stage (%)

Stage II

26 (46.4)

10 (41.7)

—

3.21E-01

Chisq Test

Stage III

26 (46.4)

14 (58.3)

—

Stage IV

4 (7.1)

0 (0.0)

—

histological_type (%)

epithelioid

9 (16.1)

4 (16.7)

25 (37.3)

5.48E-03

Chisq Test

mixed

27 (48.2)

10 (41.7)

13 (19.4)

spindle

20 (35.7)

10 (41.7)

29 (43.3)

chromosome.3.status (%)

disomy

25 (44.6)

13 (54.2)

—

5.91E-01

Chisq Test

monosomy

31 (55.4)

11 (45.8)

—

MetStatus (%)

Metastatic

20 (35.7)

6 (25.0)

18 (26.9)

4.79E-01

Chisq Test

Non-metastatic

36 (64.3)

18 (75.0)

49 (73.1)

vital_status (%)

alive

40 (71.4)

17 (70.8)

51 (76.1)

8.00E-01

Chisq Test

dead

16 (28.6)

7 (29.2)

16 (23.9)

SCNA_Cluster (%)

A

8 (14.3)

7 (29.2)

—

2.78E-01

Chisq Test

B

17 (30.4)

6 (25.0)

—

C

18 (32.1)

4 (16.7)

—

D

13 (23.2)

7 (29.2)

—